Andrea Wang-Gillam, M.D., Ph.D.
Affiliations: | 2001 | Washington Univ. School Medicine |
Area:
Pancreatic cancerWebsite:
http://oncology.wustl.edu/people/faculty/Wang-Gillam/Wang-Gillam_Bio.htmlGoogle:
"Andrea Wang-Gillam"Parents
Sign in to add mentor| Alan D. Elbein | grad student | 2001 | UAMS | |
| (Cloning, expression and characterization of UDP -HexNAc pyrophosphorylase.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Barzi A, Weipert CM, Espenschied CR, et al. (2024) (HER2) amplifications and co-occurring alterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER2 inhibition. Frontiers in Oncology. 14: 1339302 |
| Wang-Gillam A, Lim KH, McWilliams R, et al. (2023) Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 29: 4698 |
| Grierson PM, Suresh R, Tan B, et al. (2023) A pilot study of paricalcitol plus nanoliposomal irinotecan and 5-FU/LV in advanced pancreatic cancer patients after progression on gemcitabine-based therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Huffman BM, Basu Mallick A, Horick NK, et al. (2023) Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial. Jama Network Open. 6: e2249720 |
| Grierson PM, Tan B, Pedersen KS, et al. (2022) Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma. The Oncologist |
| Wang-Gillam A, Lim KH, McWilliams R, et al. (2022) Defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment refractory pancreatic cancer: A phase I, dose escalation, and expansion study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Noel MS, Kim S, Hartley ML, et al. (2022) A randomized phase II study of SM-88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond. Cancer Medicine |
| Yarchoan M, Cope L, Ruggieri AN, et al. (2021) Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. The Journal of Clinical Investigation. 131 |
| Amin M, Gao F, Terrero G, et al. (2021) Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors. American Journal of Clinical Oncology |
| Hassanzadeh C, Rudra S, Bommireddy A, et al. (2021) Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation. Advances in Radiation Oncology. 6: 100506 |